Qiagen has acquired an exclusive global license from the University of Tokyo for the biomarker SF3B1. The company said it sees potential for developing companion diagnostics to guide myelodysplastic syndromes (MDS) treatment with new anticancer compounds under development that target the SF3B1 gene.
{iframe}http://www.genengnews.com/gen-news-highlights/qiagen-adds-cancer-biomarkers-to-personalized-healthcare-pipeline/81250154/{/iframe}